Wire Stories

Category Added in a WPeMatico Campaign

Ranok_Tx_Logo

Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP™ Protein Degrader

Study will evaluate the first protein degrader developed using Ranok’s innovative CHAMP™ technology in patients with advanced solid tumors or...

Imperative_Care_Primary_Logo_RGB_M02_-_BW

Imperative Care Announces Positive New Data Underscoring the Safety and Efficacy of the Zoom Stroke Solution to Treat Distal Occlusions in Ischemic Stroke Patients

Independent Data Presented at the World Federation of Interventional and Therapeutic Neuroradiology 2022 Annual Meeting Highlights the Benefits of Vessel-Matching...